Although human papillomavirus (HPV) was detected in 40% of pregnant women, only 7.2% of neonates tested positive for HPV.
Infection with vaginal human papillomavirus (HPV) is common among pregnant women; however, perinatal transmission to infants is infrequent, new study results suggest.
Findings were published in JAMA Pediatrics,1 and data also showed no infection that was detected at the time of birth in the cohort persisted after 6 months.
“Although HPV was detected in placentas, it remains difficult to differentiate contamination vs true infection,” authors wrote.
HPV is the most common sexually transmitted infection and the leading cause of cervical cancer. The highest prevalence of the infection is found during the ages of peak fertility, which for most women are late teens through their late 20s.2
“Because of the potential for perinatal transmission of HPV, more information is needed on the frequency and dynamics of transmission, especially because recent evidence suggests that newborns may acquire HPV perinatally and that HPV may influence pregnancy outcomes,” researchers explained.
To address this knowledge gap, investigators carried out the Human Papillomavirus Perinatal Transmission and Risk of HPV Persistence Among Children (HERITAGE) study. Participants were recruited from November 2010 to October 2016, and follow-up visits were completed in June 2017.
All individuals were at least 18 years old and no more than 14 weeks pregnant. They were recruited from 3 academic hospitals in Canada.
For those with HPV-positive samples collected during their first trimester, additional samples were taken in the third trimester. Swabs and biopsies were used to test for HPV on placental samples of all participants. Researchers also tested for HPV in children at birth, after 3 months, and after 6 months.
Just over 1000 women took part in the study. The average participant age was around 31. At the time of recruitment, 40.3% of women had an HPV infection. Of the 422 women who tested positive, 280 had at least 1 high-risk genotype, the authors wrote, while 190 were coinfected with at least 2 genotypes.
Analyses also revealed these findings:
Most participants (84.9%) had not received an HPV vaccine. HPV-53, HPV-62, HPV-16, and HPV-89 were the most commonly detected genotypes.
“Among HPV-positive women in the first trimester, the percentage of women still infected with at least 1 of the same genotype in the third trimester was 72.2% (95% CI, 67.4%-76.5%), and the percentage of women in whom at least 1 new genotype was detected in the third trimester was 28.3% (95% CI, 24.0%- 33.1%),” the authors added.
Several factors can affect whether HPV is detected in the placenta, including the mother’s HPV status during pregnancy and the mode of delivery.
The researchers did not test all participants for HPV in the third trimester, marking a limitation. In addition, due to the rare nature of several HPV genotypes, they were unable to conduct a genotype-specific analysis in the current study.
“The fact that HPV was detected in 3.9% of biopsies performed under the membrane of the fetal side of the placenta suggests that although infrequent, true placental infection is possible,” authors concluded.
“Follow-up data through 5 years will be crucial in confirming if the HPV found in newborns has been cleared or if some virus remained undetected in basal cells and can reactivate later in childhood,” they wrote.
Referenceas
1. Khayargoli P, Niyibizi J, Mayrand MH, et al. Human Papillomavirus transmission and persistence in pregnant women and neonates. JAMA Pediatr. Published online May 22, 2023. doi:10.1001/jamapediatrics.2023.1283
2. Having a baby after age 35: how aging affects fertility and pregnancy. American College of Obstetricians and Gynecologists. Updated February 2023. Accessed July 14, 2023. https://www.acog.org/womens-health/faqs/having-a-baby-after-age-35-how-aging-affects-fertility-and-pregnancy#:~:text=A%20woman's%20peak%20reproductive%20years,you%20reach%20your%20mid%2D30s
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More